Benzatropine mesilate

CLINICAL USE

  • Parkinson’s disease
  • Drug-induced extrapyramidal side effects

    DOSE IN NORMAL RENAL FUNCTION

    IV/IM (emergency use): 1–2 mg

    PHARMACOKINETICS

  • Molecular weight                           :403.5
  • %Protein binding                           :95
  • %Excreted unchanged in urine     : Majority (as unchanged drug and metabolites)
  • Volume of distribution (L/kg)       :
  • half-life – normal/ESRD (hrs)      :

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Start with low doses and adjust according to response
  • 10 to 20     : Start with low doses and adjust according to response
  • <10           : Start with low doses and adjust according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
  • HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsPhenothiazines and tricyclic anti- depressants: may cause paralytic ileus which can be fatal

    ADMINISTRATION

    Reconstition

    Route

    IV, IM

    Rate of Administration

    Comments

    OTHER INFORMATION

  • Benzatropine pharmacokinetics are not well studied, but the drug apparently is hepatically metabolised to conjugates and may undergo entero-hepatic recycling
  • Benzatropine has a cumulative effect and a prolonged duration of action; therefore, treatment should commence with the lowest possible dosage and be titrated according to response
  • Related News